Company news

Valneva SE news in 2026

Valneva SE's news releases, calls and decks from 2026, newest first.

View company

Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026

November 4, 2026

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

October 14, 2026

Valneva Provides Update on IXCHIQ® in the United Kingdom

October 7, 2026

Declaration of shares and voting rights - Status as of September 30, 2026

October 5, 2026

Declaration of shares and voting rights - Status as of August 31, 2026

September 4, 2026

Déclaration d’actions et de droits de vote - Statut au 31 août 2026

September 3, 2026

Pfizer et Valneva annoncent l’acceptation pour revue par l’Agence européenne des médicaments (EMA) de la demande d’autorisation de mise sur le marché de leur candidat vaccin contre la maladie de Lyme

August 13, 2026

Valneva Half-Year 2026 Financial Report

August 12, 2026

Declaration of shares and voting rights - Status as of July 31, 2026

August 5, 2026

Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026

July 22, 2026

Declaration voting rights - June 30,2026

July 2, 2026

Valneva Announces Successful Outcome of its Annual General Meeting

June 25, 2026

Valneva Announces Availability of Documentation for its Annual General Meeting

June 4, 2026

VALNEVA: Declaration of shares and voting rights - Status as of May 31, 2026

June 3, 2026

Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 13, 2026

Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026

May 6, 2026

VALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026

May 5, 2026

Valneva Announces the Successful Completion of an €84 million Reserved Offering

April 30, 2026

Declaration of shares and voting rights of Valneva SE – March 2026

April 3, 2026

Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC

March 26, 2026

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

March 23, 2026

Valneva Reports Full Year 2025 Audited Consolidated Financial Results

March 18, 2026

Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026

March 9, 2026

VALNEVA Declaration of shares and voting rights: February 28, 2026

March 6, 2026

Valneva to Participate in Upcoming Investor Conferences

March 2, 2026

Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook

February 19, 2026

Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom

February 13, 2026

VALNEVA Declaration of shares and voting rights: January 31, 2026

February 11, 2026

Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®

February 3, 2026

Valneva Provides Update on Chikungunya Vaccine IXCHIQ®

January 19, 2026

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

January 9, 2026

Valneva SE - Declaration of voting rights - December 2025

January 8, 2026

Calls in 2026

Decks in 2026